Trials / Recruiting
RecruitingNCT05541822
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
A Phase 2 Multicenter, Open-Label, Parallel Cohort Expansion Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-Mesenchymal-epithelial Transition Factor (c-MET) Dysregulation
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 178 (estimated)
- Sponsor
- Abion Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.
Detailed description
This study will start with one cohort and it will be a parallel cohort expansion study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vabametkib | Tablets Route of Administration: Oral |
| DRUG | Lazertinib | Tablets Route of Administration: Oral |
Timeline
- Start date
- 2023-01-17
- Primary completion
- 2029-02-01
- Completion
- 2029-02-01
- First posted
- 2022-09-15
- Last updated
- 2025-05-22
Locations
24 sites across 3 countries: United States, South Korea, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05541822. Inclusion in this directory is not an endorsement.